文献速递贫血与红细胞疾病

联合限制铁与调节促红细胞生成素活性治疗纠正β地中海贫血

Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
PubMed 文献 · Blood · 2020-01-01

本研究在β地中海贫血中间型(Hbbth3/+)小鼠中,将Tmprss6反义寡核苷酸(ASO)分别与促红细胞生成素(EPO)给药或骨髓中去除单个Tfr2等位基因联合。单用EPO或去除单个Tfr2等位基因可升高血红蛋白和红细胞,但分别加重或未改善脾大;Tmprss6-ASO联合EPO或联合去除单个Tfr2等位基因产生显著更高的血红蛋白水平并减轻脾大。

要点

  • 单用EPO或去除单个Tfr2等位基因可升高β地中海贫血中间型小鼠的血红蛋白和红细胞。
  • 单用EPO加重脾大,去除单个Tfr2等位基因未改善脾大。
  • Tmprss6-ASO联合EPO或联合去除单个Tfr2等位基因较单药显著提高血红蛋白并减轻脾大。

核心结论

  • 结果表明,这些联合方案在改善β地中海贫血无效造血和贫血方面优于单药治疗,可为将这些方案转化为可行疗法提供指导。

研究设计与样本

  • 在β地中海贫血中间型(Hbbth3/+)小鼠中,将Tmprss6-ASO与EPO给药或骨髓中去除单个Tfr2等位基因联合。

主要发现

  • 单用EPO或去除单个Tfr2等位基因可升高血红蛋白水平和红细胞。
  • 单用EPO加重脾大,去除单个Tfr2等位基因未改善脾大。
  • Tmprss6-ASO联合EPO或联合去除单个Tfr2等位基因产生显著更高的血红蛋白水平并减轻脾大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Thalassemia intermedia is a disorder characterized by ineffective erythropoiesis (IE), anemia, splenomegaly, and systemic iron overload. Novel approaches are being explored based on the modulation of pathways that reduce iron absorption (ie, using hepcidin activators like Tmprss6-antisense oligonucleotides [ASOs]) or increase erythropoiesis (by erythropoietin [EPO] administration or modulating the ability of transferrin receptor 2 [Tfr2] to control red blood cell [RBC] synthesis). Targeting Tmprss6 messenger RNA by Tmprss6-ASO was proven to be effective in improving IE and splenomegaly by inducing iron restriction. However, we postulated that combinatorial strategies might be superior to single therapies. Here, we combined Tmprss6-ASO with EPO administration or removal of a single Tfr2 allele in the bone marrow of animals affected by β-thalassemia intermedia (Hbbth3/+). EPO administration alone or removal of a single Tfr2 allele increased hemoglobin levels and RBCs. However, EPO or Tfr2 single-allele deletion alone, respectively, exacerbated or did not improve splenomegaly in β-thalassemic mice. To overcome this issue, we postulated that some level of iron restriction (by targeting Tmprss6) would improve splenomegaly while preserving the beneficial effects on RBC production mediated by EPO or Tfr2 deletion. While administration of Tmprss6-ASO alone improved the anemia, the combination of Tmprss6-ASO + EPO or Tmprss6-ASO + Tfr2 single-allele deletion produced significantly higher hemoglobin levels and reduced splenomegaly. In conclusion, our results clearly indicate that these combinatorial approaches are superior to single treatments in ameliorating IE and anemia in β-thalassemia and could provide guidance to translate some of these approaches into viable therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Casu C, Pettinato M, Liu A, et al. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood. 2020. PMID: 32556142. doi:10.1182/blood.2019004719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。